302440 - SK Bioscience Co., Ltd.

302440 Summary

Biopharma

Stock Price & Overview

₩37,900 +150 (+0.40%) Close · Sep 4, 2026 KST

KOSPI | ₩KRW | Close: ₩37,900 ≈ US$27 · Market cap ₩3.0tn (≈ $2.1bn)

302440 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Total Revenue	651.4	267.5	369.5	456.7	929.0	225.6
Cost of Revenue	575.4	236.6	227.3	217.1	358.7	130.3
Gross Profit	75.9	31.0	142.2	239.6	570.3	95.3
Selling, General & Administrative	199.4	169.4	154.2	124.6	96.1	57.6
Operating Income	-123.5	-138.4	-12.0	115.0	474.2	37.7
Finance Income	49.7	45.5	90.2	116.6	26.2	7.9
Finance Costs	44.8	21.7	70.9	85.4	31.6	10.2
Pretax Income	-85.9	-89.1	7.3	141.7	471.1	37.3
Income Tax Expense	-29.7	-39.0	-15.0	19.3	116.0	4.4
Net Income	-56.2	-50.1	22.3	122.5	355.1	32.9
Total Comprehensive Income	9.5	34.4	-38.8	128.4	353.3	30.8

Breakdown ₩ tn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Total Assets	2.96	2.84	1.85	2.14	2.11	0.56
Current Assets	1.25	1.58	1.38	1.78	1.84	0.33
Cash & Cash Equivalents	0.11	0.31	0.13	0.23	0.10	0.02
Inventories	0.19	0.21	0.08	0.19	0.14	0.07
Trade Receivables	0.13	0.19	0.02	0.09	0.05	0.05
Non-current Assets	1.71	1.27	0.47	0.36	0.27	0.23
Property, Plant & Equipment	1.13	0.97	0.30	0.26	0.21	0.18
Intangible Assets	—	—	—	0.02	0.02	0.02
Total Liabilities	0.92	0.82	0.15	0.40	0.51	0.30
Current Liabilities	0.33	0.31	0.14	0.38	0.46	0.18
Non-current Liabilities	0.59	0.51	0.01	0.02	0.05	0.12
Total Equity	2.04	2.02	1.70	1.74	1.60	0.26
Share Capital	0.04	0.04	0.04	0.04	0.04	0.03
Retained Earnings	0.45	0.50	0.55	0.53	0.41	0.05

Breakdown ₩ tn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Cash from Operating Activities	0.10	-0.13	0.03	-0.12	0.54	0.12
Cash from Investing Activities	-0.36	0.05	-0.05	0.27	-1.42	-0.11
Purchase of Property, Plant & Equipment	0.18	0.16	0.04	0.07	0.04	0.01
Cash from Financing Activities	0.04	0.25	-0.09	-0.02	0.96	-0.00
Net Change in Cash	-0.22	0.18	-0.11	0.13	0.07	0.01

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	155.7	168.6	184.2	150.8	161.9	154.6	156.8	61.6	26.8	22.3
Cost of Revenue	114.2	153.8	179.2	117.8	150.0	128.4	151.2	59.8	8.6	16.9
Gross Profit	41.5	14.9	5.0	32.9	11.9	26.1	5.6	1.8	18.1	5.4
Selling, General & Administrative	57.3	59.4	56.6	52.3	49.3	41.3	56.4	41.4	38.1	33.5
Operating Income	-15.7	-44.5	-51.6	-19.4	-37.4	-15.1	-50.8	-39.6	-19.9	-28.1
Finance Income	8.5	9.7	8.2	20.1	8.9	12.5	12.1	14.7	8.1	10.7
Finance Costs	9.7	13.3	8.6	17.6	6.9	11.7	10.8	4.7	3.5	2.7
Pretax Income	-16.4	-47.8	-21.3	-15.6	-35.2	-13.8	-21.7	-30.7	-16.9	-19.8
Income Tax Expense	-2.4	-11.7	35.1	-36.7	-18.4	-9.7	19.1	8.3	5.5	-6.1
Net Income	-14.1	-36.2	-56.4	21.1	-16.8	-4.1	-2.7	-22.3	-11.4	-13.7
Total Comprehensive Income	-0.8	-14.3	-38.6	46.1	-16.0	17.9	18.8	-18.3	46.3	-12.3

Breakdown ₩ tn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	2.98	2.99	2.96	2.92	2.85	2.90	2.84	2.05	1.97	1.92
Current Assets	1.20	1.25	1.25	1.37	1.44	1.55	1.58	1.50	1.38	1.39
Cash & Cash Equivalents	0.13	0.09	0.11	0.16	0.24	0.31	0.31	0.51	0.29	0.23
Inventories	0.22	0.19	0.19	0.22	0.20	0.22	0.21	0.11	0.13	0.10
Trade Receivables	0.14	0.15	0.13	0.13	0.13	0.13	0.19	0.05	0.03	0.02
Non-current Assets	1.78	1.74	1.71	1.55	1.42	1.35	1.27	0.54	0.59	0.53
Property, Plant & Equipment	1.16	1.14	1.13	1.11	1.07	1.03	0.97	0.40	0.37	0.35
Intangible Assets	—	—	—	—	—	—	—	0.03	0.02	0.02
Total Liabilities	0.97	0.97	0.92	0.85	0.83	0.86	0.82	0.33	0.23	0.23
Current Liabilities	0.33	0.31	0.33	0.32	0.32	0.35	0.31	0.13	0.14	0.13
Non-current Liabilities	0.64	0.66	0.59	0.53	0.51	0.51	0.51	0.20	0.09	0.09
Total Equity	2.01	2.02	2.04	2.07	2.02	2.04	2.02	1.72	1.74	1.69
Share Capital	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04
Retained Earnings	0.39	0.41	0.45	0.50	0.48	0.49	0.50	0.50	0.52	0.54

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	2.7	-42.5	23.7	20.7	-4.6	62.7	-12.9	-43.5	-40.0	-31.6
Cash from Investing Activities	57.9	-37.8	-128.7	-105.2	-52.6	-75.3	-267.8	162.3	98.4	60.6
Purchase of Property, Plant & Equipment	27.4	36.7	29.9	45.2	65.2	42.7	48.0	32.9	8.3	75.2
Cash from Financing Activities	-18.2	58.1	46.9	-1.8	-1.7	-1.8	72.2	106.4	-3.1	77.0
Net Change in Cash	42.3	-22.3	-58.1	-86.4	-58.8	-14.4	-208.5	225.2	55.3	106.0

Consolidated (CFS), from DART. 6 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

302440 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	651.4	+143.5%	+12.6%	+23.6%	—
Operating income	-123.5	—	—	—	—
Net income	-56.2	—	—	—	—
EPS	₩-716	—	—	—	—
Operating cash flow	102.5	—	—	-3.1%	—
Shareholders' equity	2,037.5	+0.7%	+5.4%	+50.5%	—

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

302440 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	11.7%	11.6%	38.5%	52.5%	61.4%	42.3%
Operating margin	-19.0%	-51.7%	-3.2%	25.2%	51.0%	16.7%
Net margin	-8.6%	-18.7%	6.0%	26.8%	38.2%	14.6%
Return on equity	-2.8%	-2.7%	1.3%	7.3%	38.1%	12.5%
Return on assets	-1.9%	-2.1%	1.1%	5.8%	26.6%	5.8%
Operating cash flow / revenue	15.7%	-47.8%	7.9%	-27.4%	57.8%	53.3%
Capex / revenue	28.1%	61.5%	11.8%	15.8%	4.6%	4.3%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 302440

Symbol	Last Price
298380ABL Bio Inc.	₩71,400 +5.6%
000250Samchundang Pharm	₩157,000 +1.0%
087010Peptron, Inc.	₩157,300 +7.3%
141080LigaChem Biosciences Inc.	₩92,000 +4.2%
145020Hugel, Inc.	₩244,000 +1.5%
009420Hanall Biopharma Co., Ltd.	₩54,700 +1.5%
310210Voronoi, Inc.	₩153,000 +3.9%
214370Caregen Co., Ltd.	₩44,500 +1.5%
347850D & D Pharmatech, Inc.	₩49,200 +1.4%
237690ST Pharm Co., Ltd.	₩101,200 +2.2%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.